Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 1920

1.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J, et al.

Ann Oncol. 1994 Oct;5(8):717-24.

PMID:
7826904
2.

Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.

Goldhirsch A, Gelber R.

NCI Monogr. 1986;(1):55-70.

PMID:
3774016
3.

Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG).

J Natl Cancer Inst. 2002 Jul 17;94(14):1054-65. Erratum in: J Natl Cancer Inst 2002 Sep 4;94(17):1339.

4.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

Marini G, Murray S, Goldhirsch A, Gelber RD, Castiglione-Gertsch M, Price KN, Tattersall MH, Rudenstam CM, Collins J, Lindtner J, Cavalli F, Cortés-Funes H, Gudgeon A, Forbes JF, Galligioni E, Coates AS, Senn HJ.

Ann Oncol. 1996 Mar;7(3):245-50.

5.

Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.

International Breast Cancer Study Group (IBCSG), Castiglione-Gertsch M, O'Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Nasi ML, Bonetti M, Gelber RD.

J Natl Cancer Inst. 2003 Dec 17;95(24):1833-46.

6.

Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.

Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM.

Eur J Cancer. 1998 Oct;34(11):1693-700.

PMID:
9893654
7.
8.

Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.

Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W, et al.

J Clin Oncol. 1993 Mar;11(3):454-60.

PMID:
8445420
10.

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK.

J Clin Oncol. 1994 Oct;12(10):2078-85.

PMID:
7931477
11.

Postmastectomy radiotherapy and concomitant adjuvant chemotherapy versus adjuvant chemotherapy alone in premenopausal breast cancer patients with positive axillary nodes.

Micheletti E, La Face B, Huscher A, Catalano G, Ambrosi E, Marini G, Simoncini E.

Tumori. 1998 Nov-Dec;84(6):652-8.

PMID:
10080670
12.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A.

J Clin Oncol. 2000 Apr;18(7):1412-22.

PMID:
10735888
13.

Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group.

Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, Castiglione-Gertsch M.

Int J Radiat Oncol Biol Phys. 1996 Jul 1;35(4):649-59.

PMID:
8690630
14.

Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.

Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN.

Breast J. 2002 Jan-Feb;8(1):2-9.

PMID:
11856154
15.

Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients.

International Breast Cancer Study Group.

Ann Oncol. 1990;1(1):30-5.

PMID:
2078483
16.

Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.

Tormey DC, Gray R, Taylor SG 4th, Knuiman M, Olson JE, Cummings FJ.

NCI Monogr. 1986;(1):75-80.

PMID:
3534593
17.

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.

Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.

J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393.

19.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.

Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N.

J Natl Cancer Inst Monogr. 2001;(30):62-6.

PMID:
11773294
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk